Molecular characterization and expression analysis of the porcine paraoxonase 3 (PON3) gene

Gene

Volumn 443, Issue 1-2, 2009, Pages 110-120

  Labrecque, Benoît ^a,b   Beaudry, Danièle ^a   Mayhue, Marian ^a   Hallé, Catherine ^a   Bordignon, Vilceu ^c   Murphy, Bruce D ^b   Palin, Marie France ^a  

^a SHERBROOKE RESEARCH AND DEVELOPMENT CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Adipose tissue; Gene expression; Isoform, Paraoxonase 3; Pig; SNP

Indexed keywords

ADENOSINE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 3; COMPLEMENTARY DNA; GUANOSINE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ALTERNATIVE RNA SPLICING; ANIMAL TISSUE; ARTICLE; BODY FAT; BREEDING; CONTROLLED STUDY; ENZYME ISOLATION; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GILT (SWINE); INTRAABDOMINAL FAT; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SOW (SWINE); SUBCUTANEOUS FAT; SWINE; TISSUE DISTRIBUTION;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMALS; ESTERASES; FEMALE; GENE FREQUENCY; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT; SUS SCROFA;

MUS MUSCULUS; PIERIS BRASSICAE; SUIDAE; SUS;

EID: 67449105505     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2009.04.026     Document Type: Article

References (66)

1. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., and Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 482-487
2. Applied Biosystems. ABI PRISM 7700 Sequence Detection System. User bulletin #2 (1997)
3. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., and La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1617-1624
4. Bell F.P., and Gerrity R.G. Evidence for an altered lipid metabolic state in circulating blood monocytes under conditions of hyperlipemia in swine and its implications in arterial lipid metabolism. Arterioscler. Thromb. 12 (1992) 155-162
5. Bergen W.G., and Mersmann H.J. Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J. Nutr. 135 (2005) 2499-2502
6. Burset M., Seledtsov I.A., and Solovyev V.V. Analysis of canonical and non-canonical splice sites in mammalian genomes. Nucleic Acids Res. 28 (2000) 4364-4375
7. Campo S., Sardo A.M., Campo G.M., Avenoso A., Castaldo M., D'Ascola A., Giunta E., Calatroni A., and Saitta A. Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy. Mutat. Res. 546 (2004) 75-80
8. Can. Counc. Anim. Care (CCAC). Guide to the Care and Use of Experimental Animals (1993) Ontario, Canada
9. Carlson C.S., Heagerty P.J., Hatsukami T.S., Richter R.J., Ranchalis J., Lewis J., Bacus T.J., McKinstry L.A., Schellenberg G.D., Rieder M., Nickerson D., Furlong C.E., Chait A., and Jarvik G.P. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J. Lipid Res. 47 (2006) 1014-1024
10. Draganov D.I., and La Du B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 78-88
11. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., and La Du B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275 (2000) 33435-33442
12. Draganov D.I., Sass K.M., Watson C.E., Bisgaier C.L., Reddy S.T., Teiber J.F., and La Du B.N. The N-terminal sequences of human paraoxonase-1 (PON1) and paraoxonase-3 (PON3) are responsible for their different translocation and secretion. Circulation 106 123 (2002) Abstract)
13. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., and La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46 (2005) 1239-1247
14. Dullaart, R.P., de Vries, R., Sluiter, W.J. and Voorbij, H.A., 2008. High plasma C-reactive protein is related to low paraoxonase-I activity independently of high leptin and low adiponectin in Type 2 diabetes mellitus. Clin. Endocrinol. (Oxf) doi:10.1111/j.1365-2265.2008.03306.x.
15. Erlich P.M., Lunetta K.L., Cupples L.A., Huyck M., Green R.C., Baldwin C.T., and Farrer L.A. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum. Mol. Genet. 15 (2006) 77-85
16. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., and Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114 (2004) 1752-1761
17. Gugliucci A., Hermo R., Tsuji M., and Kimura S. Lower serum paraoxonase-1 activity in type 2 diabetic patients correlates with nitrated apolipoprotein A-I levels. Clin. Chim. Acta 368 (2006) 201-202
18. Gutteridge A., and Thornton J.M. Understanding nature's catalytic toolkit. Trends Biochem. Sci. 30 (2005) 622-629
19. Hegele R.A., Connelly P.W., Scherer S.W., Hanley A.J., Harris S.B., Tsui L.C., and Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82 (1997) 3373-3377
20. Houde A.A., Murphy B.D., Mathieu O., Bordignon V., and Palin M.F. Characterization of swine adiponectin and adiponectin receptor polymorphisms and their association with reproductive traits. Anim. Genet. 39 (2008) 249-257
21. Humphray S.J., Scott C.E., Clark R., Marron B., Bender C., Camm N., Davis J., Jenks A., Noon A., Patel M., Sehra H., Yang F., Rogatcheva M.B., Milan D., Chardon P., Rohrer G., Nonneman D., de Jong P., Meyers S.N., Archibal A., Beever J.E., Schook L.B., and Rogers J. A high utility integrated map of the pig genome. Genome Biol. 8 (2007) R139
22. Keaney Jr. J.F., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., Massaro J.M., Sutherland P., Vita J.A., and Benjamin E.J. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 434-439
23. Khersonsky O., and Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 281 (2006) 7649-7656
24. Labrecque B., Mathieu O., Bordignon V., Murphy B.D., and Palin M.F. Identification of differentially expressed genes in a porcine in vivo model of adipogenesis using suppression subtractive hybridization. Comp. Biochem. Phys. D. 4 (2009) 32-44
25. Leus F.R., Zwart M., Kastelein J.J., and Voorbij H.A. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154 (2001) 641-649
26. Lord E., Ledoux S., Murphy B.D., Beaudry D., and Palin M.F. Expression of adiponectin and its receptors in swine. J. Anim. Sci. 83 (2005) 565-578
27. Lunney J.K. Advances in swine biomedical model genomics. Int. J. Biol. Sci. 3 (2007) 179-184
28. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286 (1991) 152-154
29. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., and Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
30. Mackness B., Hine D., McElduff P., and Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 186 (2006) 396-401
31. Mackness B., Quarck R., Verreth W., Mackness M., and Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1545-1550
32. Mahley R.W., Weisgraber K.H., Innerarity T., Brewer H.B., and Assman G. Swine lipoproteins and atherosclerosis: changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. Biochemistry 14 (1975) 2817-2823
33. Marsillach J., Mackness B., Mackness M., Riu F., Beltran R., Joven J., and Camps J. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic. Biol. Med. 45 (2008) 146-157
34. Mersmann H.J. The pig: a concise source of information. In: Stanton H.C., and Mersmann H.J. (Eds). Swine in Cardiovascular Research (1986), CRC Press, Boca Raton 1-9
35. Mitra N., Sinha S., Ramya T.N., and Surolia A. N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends Biochem. Sci. 31 (2006) 156-163
36. Mochizuki H., Scherer S.W., Xi T., Nickle D.C., Majer M., Huizenga J.J., Tsui L.C., and Prochazka M. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213 (1998) 149-157
37. Moghadasian M.H. Experimental atherosclerosis: a historical overview. Life Sci. 70 (2002) 855-865
38. Nafikov R.A., and Beitz D.C. Carbohydrate and lipid metabolism in farm animals. J. Nutr. 137 (2007) 702-705
39. Navarro M.A., Acin S., Carnicer R., Guzman-Garcia M.A., Arbones-Mainar J.M., Surra J.C., Cebrian J.A., Arnal C., Isabel B., Lopez-Bote C.J., and Osada J. Response of ApoA-IV in pigs to long-term increased dietary oil intake and to the degree of unsaturation of the fatty acids. Br. J. Nutr. 92 (2004) 763-769
40. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
41. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., and Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radic. Biol. Med. 38 (2005) 153-163
42. Ng C.J., Bourquard N., Grijalva V., Hama S., Shih D.M., Navab M., Fogelman A.M., Lusis A.J., Young S., and Reddy S.T. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J. Biol. Chem. 281 (2006) 29491-29500
43. Ng C.J., Bourquard N., Hama S.Y., Shih D., Grijalva V.R., Navab M., Fogelman A.M., and Reddy S.T. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1368-1374
44. Olusi S.O. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 1159-1164
45. Ozols J. Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem. J. 338 Pt 2 (1999) 265-272
46. Palin M.F., Labrecque B., Beaudry D., Mayhue M., Bordignon V., and Murphy B.D. Visfatin expression is not associated with adipose tissue abundance in the porcine model. Domest. Anim. Endocrinol. 35 (2008) 58-73
47. Pasdar A., Ross-Adams H., Cumming A., Cheung J., Whalley L., St Clair D., and MacLeod M.J. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med. Genet. 7 28 (2006)
48. Primo-Parmo S.L., Sorenson R.C., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
49. Reddy S.T., Wadleigh D.J., Grijalva V., Ng C., Hama S., Gangopadhyay A., Shih D.M., Lusis A.J., Navab M., and Fogelman A.M. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 542-547
50. Rosenblat M., Draganov D., Watson C.E., Bisgaier C.L., La Du B.N., and Aviram M. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 468-474
51. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., and Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281 (2006) 7657-7665
52. Sanghera D.K., Aston C.E., Saha N., and Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 62 (1998) 36-44
53. Sanghera D.K., Manzi S., Minster R.L., Shaw P., Kao A., Bontempo F., and Kamboh M.I. Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann. Hum. Genet. 72 (2008) 72-81
54. SAS Statistical Analysis System. Release 9.1 (2002), SAS Institute Inc, Cary NC
55. Senti M., Tomas M., Fito M., Weinbrenner T., Covas M.I., Sala J., Masia R., and Marrugat J. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88 (2003) 5422-5426
56. Shamir R., Hartman C., Karry R., Pavlotzky E., Eliakim R., Lachter J., Suissa A., and Aviram M. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic. Biol. Med. 39 (2005) 336-344
57. Sheets M.D., Ogg S.C., and Wickens M.P. Point mutations in AAUAAA and the poly (A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. Nucleic Acids Res. 18 (1990) 5799-5805
58. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
59. Shih D.M., Xia Y.R., Wang X.P., Wang S.S., Bourquard N., Fogelman A.M., Lusis A.J., and Reddy S.T. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ. Res. 100 (2007) 1200-1207
60. Smith C.W., and Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem. Sci. 25 (2000) 381-388
61. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., and La Du B.N. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2214-2225
62. Sorenson R.C., Primo-Parmo S.L., Kuo C.L., Adkins S., Lockridge O., and La Du B.N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7187-7191
63. Tafe L.J., Belloni D.R., and Tsongalis G.J. Detection of the C282Y and H63D polymorphisms associated with hereditary hemochromatosis using the ABI 7500 fast real time PCR platform. Diagn. Mol. Pathol. 16 (2007) 112-115
64. Teiber J.F., Draganov D.I., and La Du B.N. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol. 66 (2003) 887-896
65. Terpstra A.H., Sanchez-Muniz F.J., West C.E., and Woodward C.J. The density profile and cholesterol concentration of serum lipoproteins in domestic and laboratory animals. Comp. Biochem. Physiol. B 71 (1982) 669-673
66. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., and Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490